Rhumbline Advisers Collegium Pharmaceutical, Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 102,308 shares of COLL stock, worth $3.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,308
Previous 107,364 4.71%
Holding current value
$3.07 Million
Previous $3.46 Million 14.35%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$31.4 - $39.07 $158,758 - $197,537
-5,056 Reduced 4.71%
102,308 $3.95 Million
Q2 2024

Aug 01, 2024
BUY
$31.36 - $39.99 $93,013 - $118,610
2,966 Added 2.84%
107,364 $3.46 Million
Q1 2024

May 09, 2024
SELL
$31.23 - $40.91 $117,081 - $153,371
-3,749 Reduced 3.47%
104,398 $4.05 Million
Q4 2023

Feb 08, 2024
SELL
$21.16 - $30.8 $38,828 - $56,518
-1,835 Reduced 1.67%
108,147 $3.33 Million
Q3 2023

Nov 09, 2023
BUY
$21.23 - $24.28 $20,975 - $23,988
988 Added 0.91%
109,982 $2.46 Million
Q2 2023

Aug 08, 2023
BUY
$21.06 - $24.0 $137,163 - $156,312
6,513 Added 6.36%
108,994 $2.34 Million
Q1 2023

May 11, 2023
BUY
$23.0 - $29.88 $165,255 - $214,687
7,185 Added 7.54%
102,481 $2.46 Million
Q4 2022

Feb 14, 2023
BUY
$16.14 - $23.55 $3,050 - $4,450
189 Added 0.2%
95,296 $2.21 Million
Q3 2022

Nov 10, 2022
BUY
$15.46 - $20.1 $27,055 - $35,175
1,750 Added 1.87%
95,107 $1.52 Million
Q2 2022

Aug 11, 2022
SELL
$14.22 - $20.88 $40,768 - $59,862
-2,867 Reduced 2.98%
93,357 $1.65 Million
Q1 2022

May 12, 2022
BUY
$17.2 - $22.5 $94,754 - $123,952
5,509 Added 6.07%
96,224 $1.96 Million
Q4 2021

Feb 10, 2022
BUY
$17.5 - $21.35 $20,282 - $24,744
1,159 Added 1.29%
90,715 $1.7 Million
Q3 2021

Nov 12, 2021
SELL
$17.75 - $25.39 $204,036 - $291,858
-11,495 Reduced 11.38%
89,556 $1.77 Million
Q2 2021

Aug 05, 2021
SELL
$21.74 - $25.28 $72,524 - $84,334
-3,336 Reduced 3.2%
101,051 $2.39 Million
Q1 2021

May 06, 2021
BUY
$19.25 - $26.1 $1.09 Million - $1.48 Million
56,692 Added 118.86%
104,387 $2.47 Million
Q4 2020

Feb 10, 2021
SELL
$17.83 - $22.29 $1,444 - $1,805
-81 Reduced 0.17%
47,695 $955,000
Q3 2020

Nov 12, 2020
SELL
$15.78 - $20.82 $134,492 - $177,448
-8,523 Reduced 15.14%
47,776 $995,000
Q2 2020

Aug 13, 2020
BUY
$15.49 - $23.51 $139,255 - $211,354
8,990 Added 19.0%
56,299 $985,000
Q1 2020

May 06, 2020
BUY
$13.89 - $25.45 $24,251 - $44,435
1,746 Added 3.83%
47,309 $773,000
Q4 2019

Feb 05, 2020
BUY
$10.7 - $22.24 $10,090 - $20,972
943 Added 2.11%
45,563 $938,000
Q3 2019

Oct 23, 2019
BUY
$10.16 - $13.28 $7,172 - $9,375
706 Added 1.61%
44,620 $512,000
Q2 2019

Aug 14, 2019
BUY
$10.62 - $16.59 $57,687 - $90,116
5,432 Added 14.12%
43,914 $577,000
Q1 2019

May 01, 2019
SELL
$13.58 - $18.72 $7,278 - $10,033
-536 Reduced 1.37%
38,482 $583,000
Q4 2018

Jan 31, 2019
BUY
$14.78 - $19.68 $184,410 - $245,547
12,477 Added 47.01%
39,018 $670,000
Q3 2018

Nov 07, 2018
SELL
$14.16 - $24.3 $25,488 - $43,740
-1,800 Reduced 6.35%
26,541 $391,000
Q2 2018

Aug 06, 2018
BUY
$21.79 - $28.29 $63,539 - $82,493
2,916 Added 11.47%
28,341 $676,000
Q1 2018

May 02, 2018
BUY
$18.15 - $29.21 $4,392 - $7,068
242 Added 0.96%
25,425 $650,000
Q4 2017

Feb 09, 2018
SELL
$9.3 - $19.14 $22,785 - $46,893
-2,450 Reduced 8.87%
25,183 $465,000
Q3 2017

Nov 06, 2017
BUY
$9.15 - $11.97 $252,841 - $330,767
27,633
27,633 $290,000

Others Institutions Holding COLL

# of Institutions
255
Shares Held
38.6M
Call Options Held
100K
Put Options Held
21.1K
View Full List

About COLLEGIUM PHARMACEUTICAL, INC

COLL Quotes by TradingView
  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.02B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email